These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 23138763)

  • 1. Clinical features of CIDP with LM1-associated antibodies.
    Kuwahara M; Suzuki H; Samukawa M; Hamada Y; Takada K; Kusunoki S
    J Neurol Neurosurg Psychiatry; 2013 May; 84(5):573-5. PubMed ID: 23138763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy.
    Devaux JJ; Miura Y; Fukami Y; Inoue T; Manso C; Belghazi M; Sekiguchi K; Kokubun N; Ichikawa H; Wong AH; Yuki N
    Neurology; 2016 Mar; 86(9):800-7. PubMed ID: 26843559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies against gangliosides in patients with dementia.
    Hatzifilippou E; Koutsouraki E; Costa VG; Baloyannis SJ
    Am J Alzheimers Dis Other Demen; 2014 Dec; 29(8):660-6. PubMed ID: 24838532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoantibodies Against Dihydrolipoamide S-Acetyltransferase in Immune-Mediated Neuropathies.
    Fukami Y; Iijima M; Koike HH; Yagi S; Furukawa S; Mouri N; Ouchida J; Murakami A; Iida M; Yokoi S; Hashizume A; Iguchi Y; Imagama S; Katsuno M
    Neurol Neuroimmunol Neuroinflamm; 2024 Mar; 11(2):e200199. PubMed ID: 38181320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Membrane Proteome-Wide Screening of Autoantibodies in CIDP Using Human Cell Microarray Technology.
    Caballero-Ávila M; Lleixà C; Pascual-Goñi E; Martín-Aguilar L; Vidal-Fernandez N; Tejada-Illa C; Collet-Vidiella R; Rojas-Garcia R; Cortés-Vicente E; Turon-Sans J; Gallardo E; Olivé M; Vesperinas A; Carbayo Á; Llansó L; Martinez-Martinez L; Shock A; Christodoulou L; Dizier B; Freeth J; Soden J; Dawson S; Querol L
    Neurol Neuroimmunol Neuroinflamm; 2024 May; 11(3):e200216. PubMed ID: 38484217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CIDP diagnostic pitfalls and perception of treatment benefit.
    Allen JA; Lewis RA
    Neurology; 2015 Aug; 85(6):498-504. PubMed ID: 26180143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different electrophysiological profiles and treatment response in 'typical' and 'atypical' chronic inflammatory demyelinating polyneuropathy.
    Kuwabara S; Isose S; Mori M; Mitsuma S; Sawai S; Beppu M; Sekiguchi Y; Misawa S
    J Neurol Neurosurg Psychiatry; 2015 Oct; 86(10):1054-9. PubMed ID: 25424435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sex differences in Guillain Barré syndrome, chronic inflammatory demyelinating polyradiculoneuropathy and experimental autoimmune neuritis.
    McCombe PA; Hardy TA; Nona RJ; Greer JM
    Front Immunol; 2022; 13():1038411. PubMed ID: 36569912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibodies to Glycolipids in Guillain-Barré Syndrome, Miller Fisher Syndrome and Related Autoimmune Neurological Diseases.
    Kusunoki S
    Adv Neurobiol; 2023; 29():479-495. PubMed ID: 36255685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency and clinical correlates of anti-nerve antibodies in a large population of CIDP patients included in the Italian database.
    Liberatore G; De Lorenzo A; Giannotta C; Manganelli F; Filosto M; Cosentino G; Cocito D; Briani C; Cortese A; Fazio R; Lauria G; Clerici AM; Rosso T; Marfia GA; Antonini G; Cavaletti G; Carpo M; Doneddu PE; Spina E; Cotti Piccinelli S; Peci E; Querol L; Nobile-Orazio E
    Neurol Sci; 2022 Jun; 43(6):3939-3947. PubMed ID: 35048233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Immunological and Therapeutic Insights in Guillain-Barré Syndrome and CIDP.
    Querol L; Lleixà C
    Neurotherapeutics; 2021 Oct; 18(4):2222-2235. PubMed ID: 34549385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macrophages and Autoantibodies in Demyelinating Diseases.
    Koike H; Katsuno M
    Cells; 2021 Apr; 10(4):. PubMed ID: 33917929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The immune response and aging in chronic inflammatory demyelinating polyradiculoneuropathy.
    Hagen KM; Ousman SS
    J Neuroinflammation; 2021 Mar; 18(1):78. PubMed ID: 33752693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolving Immunologic Perspectives in Chronic Inflammatory Demyelinating Polyneuropathy.
    Rajabally YA; Attarian S; Delmont E
    J Inflamm Res; 2020; 13():543-549. PubMed ID: 32982369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ataxic neuropathies.
    Mathis S; Duval F; Soulages A; Solé G; Le Masson G
    J Neurol; 2021 Oct; 268(10):3675-3689. PubMed ID: 32556571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathophysiology of Chronic Inflammatory Demyelinating Polyneuropathy: Insights into Classification and Therapeutic Strategy.
    Koike H; Katsuno M
    Neurol Ther; 2020 Dec; 9(2):213-227. PubMed ID: 32410146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune-mediated neuropathies.
    Kieseier BC; Mathey EK; Sommer C; Hartung HP
    Nat Rev Dis Primers; 2018 Oct; 4(1):31. PubMed ID: 30310069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies against peripheral nerve antigens in chronic inflammatory demyelinating polyradiculoneuropathy.
    Querol L; Siles AM; Alba-Rovira R; Jáuregui A; Devaux J; Faivre-Sarrailh C; Araque J; Rojas-Garcia R; Diaz-Manera J; Cortés-Vicente E; Nogales-Gadea G; Navas-Madroñal M; Gallardo E; Illa I
    Sci Rep; 2017 Oct; 7(1):14411. PubMed ID: 29089585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications.
    Querol L; Devaux J; Rojas-Garcia R; Illa I
    Nat Rev Neurol; 2017 Sep; 13(9):533-547. PubMed ID: 28708133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic Utility of Auto Antibodies in Inflammatory Nerve Disorders.
    Emilien D; Hugh W
    J Neuromuscul Dis; 2015 Jun; 2(2):107-112. PubMed ID: 27858733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.